Peter Loftus

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s drug.

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the proposal.

Eli Lilly and Novo Nordisk representatives get facetime with employers in hopes they will cover their drugs.

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain hospitals.

Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by wholesale distributors hurt sales of its diabetes drug Mounjaro and anti-obesity medicine Zepbound. +

Spravato, a depression treatment derived from club drug ketamine, was looking like a dud. Its recent success now shows a path forward for psychedelic-based medicines.

The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making custom-made versions.

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.

GE HealthCare shares are up about 1% after getting the green light late Friday from U.S. regulators to sell a new diagnostic imaging agent that analysts say could be a big seller for the [General Electric spinout](https://www.wsj.com/articles/ge-pounces-on-surging-healthcare-demand-with-spinoff-1163

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.